Table 2 Demographic profiles about the PD GWAS dataset
Study | Cases | Controls | Female cases (%) | Female control (%) | Case age at onset (mean, SD) | Control age at last exam (mean, SD) |
|---|---|---|---|---|---|---|
Baylor College of Medicine/University of Maryland | 769 | 195 | 33.81 | 69.74 | 64.83 (10.12) | 65.48 (8.31) |
Finnish Parkinson’s | 386 | 493 | 45.85 | 78.9 | 55.27 (5.64) | 92.35 (3.86) |
Harvard Biomarker Study (HBS) | 527 | 472 | 34.35 | 61.65 | 66.31 (10.07) | 69.9 (9.02) |
McGill Parkinson’s | 582 | 905 | 34.54 | 48.4 | 65.71 (9.79) | 55.79 (10.69) |
Oslo Parkinson’s Disease Study | 476 | 462 | 35.71 | 42.21 | 65.32 (9.28) | 61.85 (11.06) |
Parkinson’s Disease Biomarker’s Program (PDBP) | 512 | 282 | 38.67 | 51.06 | 64.46 (9.37) | 62.19 (10.73) |
Parkinson’s Progression Markers Initiative (PPMI) | 363 | 165 | 33.06 | 33.33 | 64.24 (9.65) | 63.79 (10.59) |
System Genomics of Parkinson’s Disease (SGPD) | 1169 | 968 | 35.24 | 53.93 | 59.88 (10.86) | 66.64 (9.65) |
Spanish Parkinson’s (IPDGC) | 2110 | 1333 | 43.13 | 54.39 | 63.92 (12.54) | 64.03 (12.59) |
Tubingen Parkinson’s disease cohort (CouragePD) | 666 | 542 | 36.04 | 57.93 | 59.89 (11.25) | 67.48 (8.41) |
Vance (dbGap phs000394) | 620 | 299 | 27.74 | 50.84 | 77.47 (8.40) | 81.98 (12.78) |
UKPDMED (CouragePD) | 1025 | 655 | 32.78 | 72.67 | NA | NA |
UKBioBank | 18,618 | 436,419 | 57.62 | 54.14 | 58.45 (7.20) | 56.69 (8.05) |
NeuroX—dbGaP (phs000918.v1.p1) | 5851 | 5866 | NA | NA | NA | NA |
All | 33,674 | 449,056 | NA | NA | NA | NA |